Trial Profile
A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects With Severe Hemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Lonoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Acronyms AFFINITY
- Sponsors CSL Behring
- 21 Jan 2021 Status changed from active, no longer recruiting to completed.
- 28 Nov 2020 As per European Clinical Trials Database record this trial has been completed in Italy.
- 20 Aug 2020 Planned End Date changed from 1 Jul 2025 to 19 Jan 2021.